Table 1 Study characteristics
From: Cryoablation for the treatment of chronic rhinitis: a systematic review
Author and reference | Study design | Sample size | Key chronic rhinitis criteria | Sex (M/F) | Mean age (range), years | Outcome measure | Industry sponsor |
|---|---|---|---|---|---|---|---|
Del Signore et al. [14] | RCT | 133 | Symptoms have been chronic for 6 months or longer, minimum TNSS score of 4 | CT: 23/45 Sham: 33/32 | CT: 52.3 ± 15.8 Sham: 58.3 ± 16.4 | TNSS RQLQ NOSE | Stryker Corporation |
Chang et al. [11] | Prospective single-arm trial | 98 | Minimum rTNSS score of 4, with a minimum score of 2 for rhinorrhea and 1 for nasal congestion | 35/63 | 58.6 ± 16.2 | rTNSS RQLQ | Stryker Corporation |
Gerka Stuyt et al. [10] | Prospective single-arm trial | 24 | Not explicitly defined | 12/12 | 60.04 ± 16.7 | TNSS | None Declared |
Hwang et al. [15] | Prospective single-arm trial | 27 | Minimum rTNSS rhinorrhea and/or congestion subscore of 2 | 10/17 | 53.3 ± 3.3 | TNSS | Arrinex, Inc. (Stryker Corporation) |
Yen et al. [16] | Prospective single-arm trial | 30 | Severe rhinorrhea and mild to severe nasal congestion lasting at least 3 months | 14/16 | 60.0 ± 15.8 | TNSS NOSE SNOT-22 Nasal Symptom VAS Mini RQLQ | Stryker Corporation |
Ow et al. [8] | Prospective, multicenter, interventional, single-arm | 91 | Chronic rhinitis for 6 months or longer, minimum TNSS score of four, with a minimum score of two for rhinorrhea, one for congestion | 36/64 | 58.8 ± 16.2 | rTNSS RQLQ | Arrinex, Inc. (Stryker Corporation) |
Virani et al. [17] | Retrospective cohort study | 14 | Patients who has persistent allergic or non-allergic rhinitis | 9/5 | 59.1 | rTNSS RQLQ | None Declared |
Yoo et al. [18] | Multi-institutional retrospective case–control study | 55 | Not explicitly defined | (25/30) | 55.3 ± 17.2 | RNS | None Declared |